Analyst Research
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$196.00
|
|
Trading Report for (ABT). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Abbott Laboratories To Separate Into Two Companies In Diversified Medical Products And Research-Based Pharmaceuticals
Abbott Laboratories announced that it plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The diversified medical products company will consist of Abbott's existing diversified medical products portfolio, including its branded generic pharmaceutical, devices, diagnostic and nutritional businesses, and will retain the Abbott name. The research-based pharmaceutical company will include Abbott's current portfolio of proprietary pharmaceuticals and biologics and will be named later.
Latest Developments for Abbott Laboratories
- Abbott Laboratories Announces New $3 Billion Share Repurchase Program; Declares Dividend
- Abbott Laboratories Announces CE Mark For Coronary Drug Eluting Stent
- Russia Rejects Abbott Laboratories Plan To Buy Petrovax-Reuters
- Abbott Laboratories Announces FDA Approval And U.S. Launch Of TECNIS Toric Intraocular Lens For Cataract Patients
Latest Key Developments in Pharmaceuticals
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 million
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 million-DJ
- Suheung Capsule Co Ltd to Merge with Subsidiary
- FDA Probes Deaths Of Two Patients On Eli Lilly And Co's Schizophrenia Drug-Reuters
- Share this
- Link this
- Digg this
Follow Reuters